Plasmalogen Metabolism by iPLA2 in Ischemic Myocardium

缺血心肌中 iPLA2 的缩醛磷脂代谢

基本信息

  • 批准号:
    6620278
  • 负责人:
  • 金额:
    $ 22.05万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2001
  • 资助国家:
    美国
  • 起止时间:
    2001-12-01 至 2005-11-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Thrombotic coronary artery occlusion has been demonstrated to contribute directly to arrhythmogenesis during myocardial ischemia suggesting that products released from or associated with an intracoronary thrombus may directly or indirectly influence the electrophysiologic properties of ischemic cardiac myocytes. Thrombin stimulation of rabbit ventricular myocytes activates a membrane-associated, Ca-independent phospholipase A2 (iPLA2) resulting in selective hydrolysis of arachidonylated plasmalogen phospholipids and increased production of lysoplasmenylcholine (LPlasC) and free arachidonic acid. Perfusion of normoxic rabbit ventricular myocytes with LPLasC produced action potential derangements and induced afterdepolarizations which would likely contribute to the initiation of arrhythmogenesis in the ischemic heart, providing a direct link between atherothrombosis and arrhythmogenesis. Additionally, thrombin stimulation of endothelial cells results in the activation of iPLA2 and the release of choline lysophospholipids. If these metabolites gain access to the ventricular myocyte sarcolemma, they may also contribute to arrhythmogenesis. The hypothesis to be tested by the proposed studies is that thrombin released from an intracoronary thrombus causes accumulation of the amphiphilic metabolite lysoplasmenyicholine (LPlasC) in the ischemic myocardium as a result of both increased production and decreased catabolism. The specific aims designed to test this hypothesis are: 1. To delineate the principal pathways for metabolism of LPlasC in isolated rabbit ventricular myocytes. 2. To determine whether choline lysophospholipids released from thrombin-stimulated endothelial cells can gain access to the cardiac myocyte sarcolemma where they could contribute to arrhythmogenesis. 3. To characterize the PLA2 isoforms in rabbit ventricular myocytes that contribute to Ca-independent PLA2 activity 4. To determine the signal transduction pathways involved in the activation of iPLA2 following thrombin stimulation of rabbit ventricular myocytes under normoxic or hypoxic conditions. These studies will provide important information regarding how arrhythmogenic substances in the coronary circulation may gain access to ischemic cardiac myocytes, the biochemical pathways involved in iPLA2 activation and the metabolic pathways responsible for LPlasC accumulation during myocardial ischemia. Our long-term objectives are to determine the metabolic pathways that are appropriate targets for novel therapeutic strategies to alleviate the morbidity and mortality of ischemic heart disease in man.
描述(由申请人提供):血栓性冠状动脉闭塞 已被证明直接有助于心肌梗死 缺血表明由缺血释放或与缺血相关的产物 冠状动脉内血栓可能直接或间接影响 缺血心肌细胞的电生理特性。凝血酶 刺激兔心室肌细胞激活膜相关的, 钙非依赖性磷脂酶A2(iPLA 2)导致选择性水解 花生四烯酸化的缩醛磷脂和增加的 溶血胞浆胆碱(LPlasC)和游离花生四烯酸。常氧灌注 LPLasC致兔心室肌细胞动作电位紊乱 和诱导的后去极化,这可能有助于 在缺血性心脏中启动血管生成, 动脉粥样硬化血栓形成和血栓形成之间的联系。此外,凝血酶 内皮细胞的刺激导致iPLA 2的激活, 释放胆碱溶血磷脂。如果这些代谢物能够进入 心室肌细胞肌膜,它们也可能有助于心肌发生。 拟议研究要检验的假设是凝血酶释放 导致两亲性的 结果,缺血心肌中的代谢物溶血质胆碱(LPlasC) 增加产量和减少卡路里。具体目标 旨在检验这一假设的是: 1.为了阐明LPlasC代谢的主要途径, 兔心室肌细胞 2.为了确定是否胆碱溶血磷脂释放从 凝血酶刺激的内皮细胞可以进入心肌细胞, 肌膜,它们可能有助于子宫内膜生成。 3.为了表征兔心室肌细胞中的PLA2亚型, 促进钙非依赖性PLA2活性 4.为了确定参与激活的信号转导途径, 凝血酶刺激下兔心室肌细胞的iPLA 2 常氧或缺氧条件下。 这些研究将提供重要的信息, 冠状循环中的物质可以进入缺血性心脏, 心肌细胞,参与iPLA 2激活的生化途径和 代谢途径负责LPlasC积累在心肌 缺血我们的长期目标是确定 是新的治疗策略的合适靶点, 人类缺血性心脏病的发病率和死亡率。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JANE MCHOWAT其他文献

JANE MCHOWAT的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JANE MCHOWAT', 18)}}的其他基金

ACTIVATION OF GROUP VI PHOSPHOLIPASE A2 ISOFORMS IN CARDIAC ENDOTHELIAL CELLS
心脏内皮细胞中 VI 组磷脂酶 A2 同工型的激活
  • 批准号:
    8361460
  • 财政年份:
    2011
  • 资助金额:
    $ 22.05万
  • 项目类别:
ENDOTHELIAL CELL PROSTAGLANDIN I(2) AND PLATELET-ACTIVATING FACTOR PRODUCTION
内皮细胞前列腺素 I(2) 和血小板激活因子的产生
  • 批准号:
    8361456
  • 财政年份:
    2011
  • 资助金额:
    $ 22.05万
  • 项目类别:
PLA2 activation by mast cell tryptase in IC
IC 中肥大细胞类胰蛋白酶激活 PLA2
  • 批准号:
    6934602
  • 财政年份:
    2003
  • 资助金额:
    $ 22.05万
  • 项目类别:
PLA2 activation by mast cell tryptase in IC
IC 中肥大细胞类胰蛋白酶激活 PLA2
  • 批准号:
    6712045
  • 财政年份:
    2003
  • 资助金额:
    $ 22.05万
  • 项目类别:
PLA2 activation by mast cell tryptase in IC
IC 中肥大细胞类胰蛋白酶激活 PLA2
  • 批准号:
    6802400
  • 财政年份:
    2003
  • 资助金额:
    $ 22.05万
  • 项目类别:
PLA2 activation by mast cell tryptase in IC
IC 中肥大细胞类胰蛋白酶激活 PLA2
  • 批准号:
    7104969
  • 财政年份:
    2003
  • 资助金额:
    $ 22.05万
  • 项目类别:
PLA2 activation by mast cell tryptase in IC
IC 中肥大细胞类胰蛋白酶激活 PLA2
  • 批准号:
    7279321
  • 财政年份:
    2003
  • 资助金额:
    $ 22.05万
  • 项目类别:
Plasmalogen Metabolism by iPLA2 in Ischemic Myocardium
缺血心肌中 iPLA2 的缩醛磷脂代谢
  • 批准号:
    6819235
  • 财政年份:
    2001
  • 资助金额:
    $ 22.05万
  • 项目类别:
Plasmalogen Metabolism by iPLA2 in Ischemic Myocardium
缺血心肌中 iPLA2 的缩醛磷脂代谢
  • 批准号:
    6684148
  • 财政年份:
    2001
  • 资助金额:
    $ 22.05万
  • 项目类别:
Plasmalogen Metabolism by iPLA2 in Ischemic Myocardium
缺血心肌中 iPLA2 的缩醛磷脂代谢
  • 批准号:
    6414253
  • 财政年份:
    2001
  • 资助金额:
    $ 22.05万
  • 项目类别:

相似海外基金

DEVELOPING A HUMAN STEM CELL-DERIVED HEART MODEL TO CHARACTERIZE A NOVEL ARRHYTHMIA SYNDROME
开发人类干细胞衍生的心脏模型来表征新型心律失常综合征
  • 批准号:
    495592
  • 财政年份:
    2023
  • 资助金额:
    $ 22.05万
  • 项目类别:
Preliminary Study to Establish Heavy Ion Ablation Therapy for Lethal Ventricular Arrhythmia
重离子消融治疗致死性室性心律失常的初步研究
  • 批准号:
    23K14885
  • 财政年份:
    2023
  • 资助金额:
    $ 22.05万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Arrhythmia Mechanisms Modulated by Intercalated Disc Extracellular Nanodomains
闰盘细胞外纳米结构域调节心律失常的机制
  • 批准号:
    10668025
  • 财政年份:
    2023
  • 资助金额:
    $ 22.05万
  • 项目类别:
The role of inflammation in the pathogenesis of atrial fibrillation: Implications for atrial remodeling pathophysiology and for early atrial arrhythmia recurrences following radiofrequency ablation and pulsed field ablation
炎症在心房颤动发病机制中的作用:对心房重塑病理生理学以及射频消融和脉冲场消融后早期房性心律失常复发的影响
  • 批准号:
    514892030
  • 财政年份:
    2023
  • 资助金额:
    $ 22.05万
  • 项目类别:
    WBP Fellowship
Development of a next-generation telemonitoring system for prognostic prediction of the onset of heart failure and arrhythmia
开发下一代远程监测系统,用于心力衰竭和心律失常发作的预后预测
  • 批准号:
    23K09597
  • 财政年份:
    2023
  • 资助金额:
    $ 22.05万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improved arrhythmia ablation via MR-guided robotic catheterization and multimodal clinician feedback
通过 MR 引导的机器人导管插入术和多模式临床医生反馈改善心律失常消融
  • 批准号:
    10638497
  • 财政年份:
    2023
  • 资助金额:
    $ 22.05万
  • 项目类别:
Prototype development and validation of soft robotic sensor arrays for mapping cardiac arrhythmia
用于绘制心律失常的软机器人传感器阵列的原型开发和验证
  • 批准号:
    10722857
  • 财政年份:
    2023
  • 资助金额:
    $ 22.05万
  • 项目类别:
The role N-terminal acetylation in dilated cardiomyopathy and associated arrhythmia
N-末端乙酰化在扩张型心肌病和相关心律失常中的作用
  • 批准号:
    10733915
  • 财政年份:
    2023
  • 资助金额:
    $ 22.05万
  • 项目类别:
A novel regulator of Ca2+ homeostasis and arrhythmia susceptibility
Ca2 稳态和心律失常易感性的新型调节剂
  • 批准号:
    10724935
  • 财政年份:
    2023
  • 资助金额:
    $ 22.05万
  • 项目类别:
Novel Stellate Ganglia Chemo-ablation Approach to Treat Cardiac Arrhythmia and Cardiac Remodeling in Heart Failure
新型星状神经节化疗消融方法治疗心律失常和心力衰竭心脏重塑
  • 批准号:
    10727929
  • 财政年份:
    2023
  • 资助金额:
    $ 22.05万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了